Bradley J. Monk, MD, FACS, FACOG - Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian Cancer

PeerView Oncology & Hematology CME/CNE/CPE Audio Podcast

English - May 15, 2020 23:00 - 34 minutes - ★★★★ - 8 ratings
Science cme medical education cme credits peerview insession inreview oncology hematology cne Homepage Download Apple Podcasts Google Podcasts Overcast Castro Pocket Casts RSS feed

Previous Episode: Farnaz Dadmanesh, MD - Increasing Importance of HER2 and HER3 Testing in the Context of an Expanding Targeted Therapies Landscape for Breast, Gastrointestinal, Lung, and Other Cancers: Latest Updates and Practical Guidance for Pathologists

Next Episode: "Hope S. Rugo, MD, FASCO - Biosimilars as Partners in Oncology: Expert Guidance on Understanding and Incorporating Biosimilar Agents in Real-World Car"

Go online to PeerView.com/BBX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in oncology discuss current evidence and clinical insights on the evolving role of poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitors in the frontline and recurrent maintenance settings in patients with ovarian cancer. Upon completion of this activity, participants should be better able to: Review the benefits of maintenance therapy on overall patient outcomes in ovarian cancer management, Summarize new evidence on and recent indications for PARP inhibitors as maintenance therapy in the frontline and recurrent advanced ovarian cancer settings, Select appropriate maintenance interventions based on patient and disease characteristics and response to prior therapy in patients with advanced ovarian cancer.